Related Experiment Videos
Pediatric head and neck rhabdomyosarcoma
C J MacArthur1, T J McGill, G B Healy
1Children's Hospital, Boston, Massachusetts 02115.
Clinical Pediatrics
|February 1, 1992
Summary
Pediatric rhabdomyosarcoma (RMS) management has improved significantly. Multimodality treatment, including advances in chemotherapy, radiation, and surgery, now offers a two-thirds long-term survival rate for affected children.
Area of Science:
- Pediatric oncology
- Surgical oncology
- Radiation oncology
Background:
- Rhabdomyosarcoma (RMS) is the most frequent soft-tissue sarcoma in children.
- Head and neck region is the most common site for pediatric RMS.
- Historically, RMS had a uniformly fatal prognosis before 1960.
Purpose of the Study:
- To review advancements in pediatric rhabdomyosarcoma management.
- To highlight the impact of multimodality treatment on survival rates.
- To emphasize the renewed role of surgery in primary RMS management.
Main Methods:
- Review of advancements in chemotherapy, radiation therapy, and surgical techniques over the past 20 years.
- Focus on the integration of skull-base, craniofacial, and free-tissue-transfer reconstructive surgery.
- Analysis of treatment outcomes in the context of multimodality regimens.
Main Results:
- Significant improvements in pediatric rhabdomyosarcoma management have been achieved.
- Modern surgical techniques have re-established surgery as a primary treatment modality.
- Multimodality treatment regimens have increased long-term survival rates.
Conclusions:
- Pediatric rhabdomyosarcoma is now a treatable malignancy.
- The combination of chemotherapy, radiation, and advanced surgical techniques is crucial for improving outcomes.
- Two-thirds of patients with pediatric rhabdomyosarcoma can now expect long-term survival.